These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 2939456)

  • 1. Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats.
    Kupiec-Weglinski JW; Diamantstein T; Tilney NL; Strom TB
    Proc Natl Acad Sci U S A; 1986 Apr; 83(8):2624-7. PubMed ID: 2939456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective immunosuppression with anti-interleukin 2 receptor-targeted therapy: helper and suppressor cell activity in rat recipients of cardiac allografts.
    Kupiec-Weglinski JW; Padberg W; Uhteg LC; Ma L; Lord RH; Araneda D; Strom TB; Diamantstein T; Tilney NL
    Eur J Immunol; 1987 Mar; 17(3):313-9. PubMed ID: 2952511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of suppressor lymphocytes during acute rejection of rat cardiac allografts and preservation of suppression by anti-IL-2-receptor monoclonal antibody.
    Schneider TM; Kupiec-Weglinski JW; Towpik E; Padberg W; Araneda D; Diamantstein T; Strom TB; Tilney NL
    Transplantation; 1986 Aug; 42(2):191-6. PubMed ID: 2943063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of interleukin 2 receptor-targeted therapy on heart and kidney allografts in rats. Depression of effectiveness of ART-18 monoclonal antibody treatment by uremia.
    Ueda H; Hancock WW; Cheung YC; Tanaka K; Kupiec-Weglinski JW; Tilney NL
    Transplantation; 1990 Jun; 49(6):1124-9. PubMed ID: 2113725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agonistic and antagonistic interactions of anti-interleukin 2 receptor monoclonal antibodies in rat recipients of cardiac allografts.
    Kupiec-Weglinski JW; Tilney NL; Stunkel KG; Grutzmann R; van der Meide PH; Di Stefano R; Diamantstein T
    Transplantation; 1989 Jan; 47(1):11-6. PubMed ID: 2463699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of IL 2R+ T cells and macrophages within rejecting rat cardiac allografts, and comparison of the effects of treatment with anti-IL 2R monoclonal antibody or cyclosporin.
    Hancock WW; Lord RH; Colby AJ; Diamantstein T; Rickles FR; Dijkstra C; Hogg N; Tilney NL
    J Immunol; 1987 Jan; 138(1):164-70. PubMed ID: 3097143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of action of anti-IL-2R monoclonal antibodies. ART-18 prolongs cardiac allograft survival in rats by elimination of IL-2R+ mononuclear cells.
    Tanaka K; Hancock WW; Osawa H; Stunkel KG; Alberghini TV; Diamantstein T; Tilney NL; Kupiec-Weglinski JW
    J Immunol; 1989 Nov; 143(9):2873-9. PubMed ID: 2530281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodistribution of anti-interleukin 2 receptor monoclonal antibodies correlates with their therapeutic efficacy following transplantation.
    Kupiec-Weglinski JW; Mariani G; Tanaka K; Di Stefano R; Stünkel KG; Diamantstein T; Tilney NL
    Cell Immunol; 1989 Oct; 123(1):148-57. PubMed ID: 2476241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of anti-interleukin-2 receptor monoclonal antibody on allograft rejection.
    Kirkman RL; Barrett LV; Gaulton GN; Kelley VE; Koltun WA; Schoen FJ; Ythier A; Strom TB
    Transplantation; 1985 Dec; 40(6):719-22. PubMed ID: 3934807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-interleukin 2 receptor monoclonal antibodies spare phenotypically distinct T suppressor cells in vivo and exert synergistic biological effects.
    Di Stefano R; Mouzaki A; Araneda D; Diamantstein T; Tilney NL; Kupiec-Weglinski JW
    J Exp Med; 1988 Jun; 167(6):1981-6. PubMed ID: 2968435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of accelerated rejection of cardiac allografts in sensitized rats by anti-interleukin 2 receptor monoclonal antibody and cyclosporine therapy.
    Kupiec-Weglinski JW; Sablinski T; Hancock WW; Di Stefano R; Mariani G; Mix CT; Tilney NL
    Transplantation; 1991 Feb; 51(2):300-5. PubMed ID: 1825240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment with cyclosporine and anti-interleukin 2 receptor antibody abrogates the anti-idiotype response in rat recipients of cardiac allografts.
    Tanaka K; Tilney NL; Stunkel KG; Hancock WW; Diamantstein T; Kupiec-Weglinski JW
    Proc Natl Acad Sci U S A; 1990 Oct; 87(19):7375-9. PubMed ID: 2217171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of acute murine cardiac allograft rejection: anti-CD4 or anti-vascular cell adhesion molecule one monoclonal antibodies block acute rejection but permit persistent graft-reactive alloimmunity and chronic tissue remodelling.
    Orosz CG; Huang EH; Bergese SD; Sedmak DD; Birmingham DJ; Ohye RG; VanBuskirk AM
    J Heart Lung Transplant; 1997 Sep; 16(9):889-904. PubMed ID: 9322138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. alpha/beta-T cell receptor-directed therapy in rat cardiac allograft recipients. Treatment prior to alloantigen exposure prevents sensitization and abrogates accelerated rejection.
    Heidecke CD; Hancock WW; Jakobs F; Zantl N; Kurrle R; Westerholt S; Sewczik T; Deusch K; Kupiec-Weglinski J
    Transplantation; 1995 Jan; 59(1):78-84. PubMed ID: 7839433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific immunosuppression of corneal allograft rejection by combination of anti-VLA-4 and anti-LFA-1 monoclonal antibodies in mice.
    Hori J; Isobe M; Yamagami S; Mizuochi T; Tsuru T
    Exp Eye Res; 1997 Jul; 65(1):89-98. PubMed ID: 9237869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific immunosuppressive therapy by monoclonal anti-IL 2 receptor antibody and its synergistic action with cyclosporin.
    Diamantstein T; Volk HD; Tilney NL; Kupiec-Weglinski J
    Immunobiology; 1986 Sep; 172(3-5):391-9. PubMed ID: 3100433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions between T lymphocyte subsets supported by interleukin 2-rich lymphokines produce acute rejection of vascularized cardiac allografts in T cell deprived rats.
    Heidecke CD; Kupiec-Weglinski JW; Lear PA; Abbud-Filho M; Araujo JL; Araneda D; Strom TB; Tilney NL
    J Immunol; 1984 Aug; 133(2):582-8. PubMed ID: 6234351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of anti-interleukin-6 monoclonal antibody prolongs cardiac allograft survival.
    Lei J; He F; Wu M; Zheng X; Chen X; Chen Z
    Transpl Int; 2010 Dec; 23(12):1271-81. PubMed ID: 20646257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence that monoclonal antibodies against the 55kD subunit of the rat IL-2 receptor do not inhibit the development of suppressor cells generated in mixed lymphocyte culture.
    Tanaka K; Turka LA; Kupiec-Weglinski JW; Milford EL; Ueda H; Diamantstein T; Carpenter CB; Tilney NL
    Transplantation; 1990 Jul; 50(1):125-31. PubMed ID: 2142344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of specific unresponsiveness to cardiac allografts by short-term administration of anti-T cell receptor alpha beta antibody.
    Tsuchida M; Hirahara H; Matsumoto Y; Abo T; Eguchi S
    Transplantation; 1994 Jan; 57(2):256-62. PubMed ID: 8310517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.